Tevogen Bio To Discusses Its Genetically Unmodified T Cell Technology For The Treatment of Infectious Diseases, Cancers, And Neurological Disorders With Nasdaq's Kristina Ayanian
Tevogen Bio To Discusses Its Genetically Unmodified T Cell Technology For The Treatment of Infectious Diseases, Cancers, And Neurological Disorders With Nasdaq's Kristina Ayanian
Tevogen Bio將與納斯達克的Kristina Ayanian討論其用於治療傳染病、癌症和神經系統疾病的基因未經修改的T細胞技術。
- Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applications
- Tevogen's ExacTcell platform is designed to address current cost, and patient accessibility challenges
- ExacTcell's first product consists of single HLA restricted, off-the-shelf, genetically unmodified T cells
- Broad application potential spanning cancer, infectious diseases, and neurological disorders
- ExacTcell platform produced hundreds of doses from a single donor, facilitating cost reduction
- Flomenberg博士和Grosso博士是T細胞生物學及其臨床應用的領先專家。
- Tevogen的ExacTcell平台旨在解決當前成本和病人可及性方面的挑戰。
- ExacTcell的第一個產品包括單個HLA限制、非基因修飾的電芯。
- 廣泛適用於癌症、傳染病和神經系統疾病治療，具有大量的應用潛力。
- ExacTcell平台可從單個供體中生產數百劑次，有助於降低成本。
WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise of T cell therapy and Tevogen's mission to make it mainstream on Nasdaq's broadcast, Live From MarketSite with Kristina Ayanian.
2024年7月10日，新澤西州禾倫（GLOBE NEWSWIRE）——Tevogen Bio Holding Inc.（“Tevogen”或“Tevogen Bio”）（納斯達克代碼：TVGN），一家臨床階段的特殊免疫治療生物技術先驅，正在開發用於腫瘤學、神經學和病毒學領域的非基因修飾的即插即用電芯治療方案。Flomenberg博士和Lori Grosso博士在納斯達克的廣播節目“Live From MarketSite with Kristina Ayanian”中討論了電芯治療的前景和Tevogen將其打造成主流的使命。